A New Era of Neuro-Oncology Research Pioneered by Multi-Omics Analysis and Machine Learning.

Journal: Biomolecules
Published Date:

Abstract

Although the incidence of central nervous system (CNS) cancers is not high, it significantly reduces a patient's quality of life and results in high mortality rates. A low incidence also means a low number of cases, which in turn means a low amount of information. To compensate, researchers have tried to increase the amount of information available from a single test using high-throughput technologies. This approach, referred to as single-omics analysis, has only been partially successful as one type of data may not be able to appropriately describe all the characteristics of a tumor. It is presently unclear what type of data can describe a particular clinical situation. One way to solve this problem is to use multi-omics data. When using many types of data, a selected data type or a combination of them may effectively resolve a clinical question. Hence, we conducted a comprehensive survey of papers in the field of neuro-oncology that used multi-omics data for analysis and found that most of the papers utilized machine learning techniques. This fact shows that it is useful to utilize machine learning techniques in multi-omics analysis. In this review, we discuss the current status of multi-omics analysis in the field of neuro-oncology and the importance of using machine learning techniques.

Authors

  • Satoshi Takahashi
    Department of Neurosurgery, University of Tokyo, Tokyo.
  • Masamichi Takahashi
    Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
  • Shota Tanaka
    Department of Neurosurgery, University of Tokyo, Tokyo. Electronic address: tanakas-tky@umin.ac.jp.
  • Shunsaku Takayanagi
    Department of Neurosurgery, University of Tokyo, Tokyo.
  • Hirokazu Takami
    Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
  • Erika Yamazawa
    Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
  • Shohei Nambu
    Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
  • Mototaka Miyake
    Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
  • Kaishi Satomi
    Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
  • Koichi Ichimura
    Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
  • Yoshitaka Narita
    Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
  • Ryuji Hamamoto
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo, Japan.